G1 THERAPEUTICS INC. - COMMON STOCK

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Jan 2022 17:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Expansion of COSELA™ (Trilaciclib) Sales Force

16 Dec 2021 06:00:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Dec 2021 18:20:00 By Nasdaq GlobeNewswire

G1 Therapeutics Initiates Phase 2 Trial to Support the Antitumor Mechanism of Action (MOA) of Trilaciclib in the Tumor Microenvironment

01 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)

29 Nov 2021 07:00:00 By Nasdaq GlobeNewswire

Immune Analysis from Phase 2 Triple Negative Breast Cancer Trial Demonstrates Trilaciclib Enhanced Patients’ T Cell Immune Function When Administered Prior to Chemotherapy

12 Nov 2021 08:25:00 By Nasdaq GlobeNewswire

G1 Therapeutics to Participate in Two Upcoming Conferences

10 Nov 2021 11:40:00 By Nasdaq GlobeNewswire

G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights

03 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Nov 2021 18:00:00 By Nasdaq GlobeNewswire

G1 Therapeutics to Provide Third Quarter 2021 Financial Results and Business Update on November 3, 2021

20 Oct 2021 08:00:02 By Nasdaq GlobeNewswire

Retrospective Analysis of Pooled Results from Three Studies Shows COSELA™ (Trilaciclib) Reduced Use of Supportive Care Interventions in Extensive Stage Small Cell Lung Cancer Patients Who Receive the Drug Prior to Chemotherapy

07 Oct 2021 08:00:02 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Oct 2021 16:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Permanent J-Code from Centers for Medicare and Medicaid Services

01 Oct 2021 07:45:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces New Supplemental COSELA™ (Trilaciclib) Sales Force

15 Sep 2021 06:45:00 By Nasdaq GlobeNewswire

G1 Therapeutics to Participate in Two Upcoming September Conferences

03 Sep 2021 07:45:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Sep 2021 07:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics Provides Second Quarter 2021 Financial Results and Operational Highlights

04 Aug 2021 16:01:00 By Nasdaq GlobeNewswire

G1 Therapeutics Granted New Technology Add-On Payment (NTAP) for COSELA™ (Trilaciclib) by Centers for Medicare & Medicaid Services (CMS)

04 Aug 2021 08:00:01 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Appointment of Andrew Perry as Chief Commercial Officer

02 Aug 2021 06:50:00 By Nasdaq GlobeNewswire

G1 Therapeutics to Provide Second Quarter 2021 Financial Results and Business Update on August 4, 2021

28 Jul 2021 08:00:02 By Nasdaq GlobeNewswire